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Abstract Matrix Gla protein (MGP) and fetuin-A are
inhibitors of arterial calcifications. In blood of rats,
calcium–phosphate–fetuin–MGP complexes, produced in
bone, have been identified. Indeed, an association between
bone resorption, release of such complexes, and arterial
calcifications has been reported. We have investigated the
synthesis and localization of fetuin-A and MGP in bone of
hemodialysis patients and the possible contribution of bone
cells in arterial calcifications. Bone biopsies from 11
hemodialysis patients were used for histology, in situ
hybridization of fetuin-A and MGP messenger RNA
(mRNA), immunohistochemistry of fetuin-A, and total,
carboxylated, and non-carboxylated MGP proteins. Patients
showed various types of renal osteodystrophy, or normal
bone. MGP was synthesized and expressed (total and
carboxylated) by osteoblasts, osteocytes, and most osteo-
clasts, while fetuin-A by osteoblasts and osteocytes. Fetuin-
A and carboxylated MGP proteins were positive in the
calcified matrix, while total MGP was negative. Osteoid
seams were negative to fetuin-A, lightly positive to
carboxylated MGP, and occasionally positive to total
MGP. Undercarboxylated MGP was mostly undetectable.
In adult humans, fetuin-A is produced also by osteoblasts,
and not only by hepatocytes, as previously believed. MGP,
essentially carboxylated, is synthesized by osteoblasts and
most osteoclasts. Increased bone turnover can be an
important contributor to arterial calcifications.
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Introduction
Vascular calcifications are of frequent occurrence in uremic
subjects, and it is assumed that they greatly contribute to
the increased cardiovascular mortality both in conservative
and hemodialysis (HD) stages of uremia [1, 2]. Several risk
factors of vascular calcifications have been identified. Age
and hemodialysis vintage are among the most important.
Also serum calcium, phosphate, CaxP product [3], as well
as the rates of hyperparathyroidism [4] and of bone
turnover [5] are considered of great importance. In addition,
inflammation and malnutrition may play a role, directly
and/or through the reduction of fetuin-A, an important
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calcium–phosphate solubilizing agent [6]. It has been
shown that fetuin-A-deficient mice develop diffuse extra-
skeletal calcifications when administered a mineral and
vitamin D-rich diet [7]. Cross-sectional analyses of patients
with end-stage renal disease have shown that lower fetuin-A
concentrations in serum are associated with more extensive
vascular and heart valve calcifications, and with increased
cardiovascular events and all-cause mortality in longitudinal
studies [8]. Fetuin-A is known to be synthesized by the liver
of adult humans, and it is found in high concentrations in
serum and bone.
Another important protein capable of controlling extra-
skeletal calcifications in experimental animal models is the
matrix Gla protein (MGP). MGP-deficient mice die in the first
weeks of life due to extensive calcifications of the vascular
tree, with consequent rigidity and rupture of the aorta [9].
MGP is a protein mainly found in bone, dentine, and
cartilage, which contains five vitamin-K-dependent γ-
carboxyglutamic acid (Gla) residues that confer it a high
affinity for calcium and phosphate ions, and for hydroxyap-
atite crystals. The presence of Gla residues, therefore, is
regarded as critical for the function of MGP, while under-
carboxylated MGP, which may result from poor vitamin K
status, is considered inactive [10, 11]. Therefore, fetuin-A
and MGP can inhibit extraosseous and specifically arterial
calcifications, as well as bone mineralization [2, 12].
However, the origin of these proteins is not entirely
known. There are reasons to believe that the bone cells may
give a contribution to the production of these substances.
Biochemical studies have demonstrated that, in the serum
of rats, fetuin and MGP form a complex with calcium and
phosphate which maintains in solution these minerals,
otherwise considered in a state of supersaturation, thus able
to mineralize extraskeletal tissues [13]. This complex, very
probably identical with the calciprotein particles detected
by using electron microscopy and dynamic light scattering
[14], is convincingly produced in the bone-remodeling
compartment (BRC) [13]. In rats, however, the administra-
tion of bisphosphonates, inhibitors of osteoclast resorption,
was found to prevent the arterial calcifications induced by
warfarin or warfarin plus vitamin D, by reducing the release
of the calcium–phosphate–fetuin–MGP complex from the
BRC [10]. Further experimental studies have shown a
direct association between increase of bone resorption,
release of the calcium-phosphate–fetuin–MGP complex,
and arterial calcifications [12]. Thus, the fetuin-A and MGP
inhibition of extraosseous and, specifically, arterial calcifi-
cations is probably exerted locally in the soft tissues and
can be somehow impaired in cases of high bone turnover
and consequent increase of the mineral-containing com-
plexes in the blood [2, 12].
The present study was carried out to evaluate the
synthesis and localization of fetuin-A and MGP directly in
bone tissue of uremic HD patients with a wide range of
bone turnover by immunohistochemistry (IHC) and in situ
hybridization (ISH). The total, carboxylated, and non-
carboxylated forms of MGP were examined. The possible
mechanism of how bone tissue, and specifically osteoclast
resorption, could be implicated in the calcium–phosphate–
fetuin–MGP complex formation is discussed.
Materials and methods
A total of 11 patients (seven men and four women;
49.45±12.26 years) with chronic renal failure in HD
treatment were considered. Each patient underwent
transiliac bone biopsy with a Bordier trocar following
a double cycle of per os administration of tetracycline
with 12 days interval. The biopsies were taken 4 to
5 days after the last dose administration. Biopsies were
fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer at pH 7.2. They were then cut longitudinally
into two halves with a razor blade and washed in buffer
solution.
One half was dehydrated in acetone and processed
for glycolmethacrylate embedding without decalcifica-
tion. Sections, 1–2 μm thick, were stained with
methylene blue-azure II for histology. Sections, about
5 μm thick, were prepared unstained for the analysis of
tetracycline fluorescent labels under UV light. Other
sections, about 3–4 μm thick, were stained with the
aluminon method. Renal osteodystrophy was diagnosed
on the basis of morphologic criteria [15, 16]. Moreover,
histomorphometric descriptors were obtained in corre-
spondence of the trabecular bone, by using an interactive
color video-based image analysis system [15], and
expressed in agreement with the American Society for
Bone and Mineral Research [17]. The variable bone
formation rate (BFR/BS, μm3/μm2/day; the volumetric
amount of new mineralized bone per unit of trabecular
bone surface per day) was considered for the evaluation of
bone turnover [18]; mineralization was examined by
osteoid volume (OV/BV, %; percent of trabecular bone
volume consisting of osteoid), osteoid thickness (O.Th,
μm; thickness of osteoid seams), and mineralization lag-
time (Mlt, days; the mean time interval between deposition
of osteoid matrix and its mineralization) results [19];
the volume of trabecular bone was given by the measure
of bone volume (BV/TV, %; percent of whole trabecular
bone volume occupied by calcified and uncalcified
bone tissue). Then, the recently proposed turnover/
mineralization/volume (TMV) classification system [16]
was applied by considering the standard deviation scores
(SDS) of the measured variables [20] in relation to our
normal control values [15].
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IHC and ISH
The other half of bone biopsy was decalcified in 10%
disodium EDTA in 0.1 M phosphate buffer at pH 7.0 and
processed for paraffin embedding. Serial sections (about 2
to 5 μm thick) were deparaffinized and treated for 10 min
with 3% H2O2 in methanol.
Slides for IHC were washed for 20 min in phosphate-
buffered saline (PBS) containing 0.1% Tween 20. For MGP
detection, sections were incubated for 10 min in the
blocking reagent of the Vectastain Universal Quick kit
(Vector Laboratories, Inc; Burlingame, CA, USA). Serial
sections were stained with monoclonal antibodies against
total (amino acids 3–15; Biodesign International®, Saco,
ME, USA; dilution 1:200), fully carboxylated (amino acids
35–54; ALEXIS® Biochemicals, Lausen, Switzerland;
dilution 1:800), and non-carboxylated (amino acids 35–
49; ALEXIS® Biochemicals, Lausen, Switzerland; dilution
1:250) MGP by overnight incubation at 4°C. Immunode-
tection with secondary biotinylated antibody and the
streptavidin–peroxidase conjugate complex was performed
by the Vectastain Universal Quick kit. The Liquid DAB+
Substrate Chromogen System (DakoCytomation, Inc.;
Carpinteria, CA, USA) was then applied, followed by a
counterstain with 1:15 diluted Mayer’s hemalum solution.
For fetuin-A IHC, sections were treated with the
Superblock reagent (Scytek Laboratories, Inc; Logan,
UT, USA). Then, the goat anti-human fetuin-A/AHSG
polyclonal antibody (R&D Systems, Inc; Minneapolis,
MN, USA) was applied (1:500 dilution) for 1 h. Immuno-
detection was performed using the LSAB2 System-HRP kit
(DakoCytomation, Inc., Carpinteria, CA, USA). The
substrate-chromagen diaminobenzidine and counterstain
with Mayer’s hemalum were utilized, as already described
for MGP IHC.
Negative controls were obtained by omitting the primary
antibodies. Positive controls for MGP and fetuin-A were
tested by using samples of arteries with atherosclerotic
disease. Moreover, samples of fetal liver were tested for
fetuin-A. For each antibody, the optimal working dilution
was chosen after testing different concentrations.
For ISH, dewaxed sections were permeabilized for 15 min
at 37°C with 75 μg/ml proteinase K (Sigma Chemical Co; St.
Louis, MO, USA) and post-fixed in paraformaldehyde 4% in
PBS-DEPC. The double FITC human MGP and the double
FITC human fetuin-A HybriProbe™ kits provided by
Biognostick® (Göttingen, Germany) were used in separate
slides, respectively. The oligonucleotide sequences of MGP
and fetuin-AHybriProbes were based on the NM_000900 and
the NM_001622 GenBank Accession number, respectively.
The specific probes were hybridized (1.5 μl HybriProbes in
25 μl HybriBuffer-ISH) overnight at 35°C. After washing in
TRIS/HCl buffer at pH 7.55 containing 5% BSA and 0.1%
Tween 20, immunodetection was performed with peroxidase
anti-FITC goat antibody (whole molecule) diluted 1:750.
Diaminobenzidine (Liquid DAB+) was used as chromogen.
Sections were counterstained with 1:15 diluted Mayer’s
hemalum solution. Positive and negative control probes
included in the HibriProbe kits were tested. Moreover,
negative controls were achieved by omitting incubation with
MGP or fetuin-A probes.
Results
The following diagnoses were assigned: four patients were
affected by osteodystrophy with predominant hyperpara-
thyroidism, showing a general increase in bone turnover,
increased numbers of osteoclasts within wide Howship’s
lacunae, and many plump osteoblasts along numerous
osteoid seams, together with areas of woven bone and
endosteal fibrosis; three patients were affected by osteodys-
trophy with predominant osteomalacia, characterized by a
decrease of bone turnover and a mineralization defect, in
which the increased osteoid seams were mostly in contact
with flat osteoblasts, while Howship’s lacunae with
osteoclasts were rarely found: two of these patients had
fully developed osteomalacia, being all three osteoid
indices (surface extent, volume, and thickness) increased,
while one of them showed the so-called atypical osteoma-
lacia, since osteoid seams were increased in surface and
volume but not in thickness [19]; one patient was affected
by mixed osteodystrophy, which includes signs of both
hyperparathyroidism and osteomalacia; one patient had
features of adynamic osteodystrophy, characterized by
reduced bone turnover, thin osteoid seams almost com-
pletely lined by flat osteoblasts, and very few osteoclasts;
two patients were free of pathologic bone lesions. The
histomorphometric TMV classification of the patients is
shown in Table 1. The aluminum staining was negative in
all patients.
MGP
In all bioptical samples, the IHC for total MGP was
negative in correspondence of the calcified bone matrix.
Moreover, no staining was found in the osteoid seams,
except for one case with advanced hyperparathyroidism and
one with severe osteomalacia in which some occasional
seams showed a lightly brownish staining. In all cases,
some positive osteocytes were found. Immunolabeling
consisted of brown aggregates inside the osteocyte cyto-
plasm. Positive cells were mainly found in correspondence
and in proximity to the osteoid seams, or within the
calcified matrix next to the quiescent endosteal surfaces.
Less frequently, some positive osteocytes were found more
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inside the calcified matrix. In adjacent sections, the ISH
messenger RNA (mRNA) labeling was mainly localized in
the cytoplasm of some osteocytes, with a similar pattern of
distribution (Fig. 1).
Apart from the case with adynamic bone disease, in
which plump osteoblasts could not be found, these cells
resulted positive to the IHC reaction both along the
trabeculae and in correspondence of cortical bone, and
independently of the type of bone alteration. These same
cells were intensely stained by ISH for mRNA (Fig. 1).
Cells of endosteal fibrosis, which could be detected in
the bone biopsies of patients with high turnover bone
disease (hyperparathyroidism and mixed type of renal
osteodystrophy), were positive to both IHC and ISH
reactions (Fig. 1).
Multinucleated osteoclasts could not be detected in one
case with severe osteomalacia. In all the other cases, most
of these cells were variably positive to total MGP IHC in
trabecular and cortical bone; however, some negative
osteoclasts were found, with no apparent difference in
frequency between the types of bone alterations. In
agreement with these findings, osteoclasts showed either
variably diffused ISH mRNA labeling in the cytoplasm or
no signal at all (Fig. 2).
In all samples, the results described above for total MGP
IHC coincided with those found by the antibody specifi-
cally recognizing the carboxylated form of the protein, in
osteocytes, osteoblasts, osteoclasts, and cells of endosteal
fibrosis (Fig. 3). For both types of IHC reaction, cell
positivity was clearly visible although the antibody con-
centrations for total MGP and for carboxylated MGP were
5 and 3.2 times lower than those suggested in the respective
product data sheet. In contrast to total MGP, in all cases, a
Fig. 1 Total MGP: a osteoblasts (arrows), endosteal fibrosis cells
(asterisk), and some young osteocytes (arrowheads) are positive to
IHC; b osteoblasts (arrows), endosteal fibrosis cells (asterisk), and
some osteocytes (arrowheads) are positive to ISH, while two
osteoclasts (empty arrows) are negative. Trabecular bone, hyperpara-
thyroidism. Bars=10 μm



















M/32 Hyperparathyroidism High High High Normal N-abnormal Normal
M/40 Hyperparathyroidism High High High N-high N-abnormal N-high
F/48 Hyperparathyroidism High High High N-low N-abnormal High
F/49 Hyperparathyroidism High High N-high Normal N-abnormal High
M/47 Osteomalacia N/A High High N/A Abnormal N/A
F/58 Osteomalacia Low High High High Abnormal N-high
M/39 Atypical osteomalacia Low High Normal High N-abnormal Low
M/41 Mixed osteodystrophy N-high High High High Abnormal High
F/71 Adynamic osteodystrophy Low Normal N-high High N-abnormal Normal
M/50 Without pathologic alteration Normal Normal Normal N-low Normal Normal
M/69 Without pathologic alteration Normal Normal Normal N-low Normal Normal
High, >2 SDS from mean; Low, <2 SDS from mean; N-high, 1–2 SDS above mean; N-low, 1–2 SDS below mean
N-abnormal mildly abnormal, N/A not available
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light and diffuse carboxylated MGP immunostaining was
found in the calcified bone matrix and in most osteoid
seams, although the staining intensity in the latter was very
faint (Fig. 3).
In some cases, independent of the type of bone
condition, some of the flat, lining cells which border the
quiescent bone surfaces were positive to the IHC reaction
for total and carboxylated MGP, as well as to the ISH
reaction for MGP mRNA. However, because their cyto-
plasm is characteristically reduced to a very thin rim, the
recognition of the labeling of these cells was generally
difficult.
Undercarboxylated MGP IHC, performed by using
exactly the antibody concentration indicated by the product
data sheet, was practically negative in all bioptical samples.
Only a very weak immunostaining was present in the
osteoid and/or calcified bone matrix of a minority of
patients, without any reference to the types of bone lesions.
In these cases, rare osteocytes, osteoblasts, and/or osteo-
clasts were very lightly stained.
Fetuin-A
The antibody dilution used for fetuin-A IHC was optimized
at a concentration which was 10 times lower than the lower
limit of the working dilution suggested by the data sheet. In
both cortical and trabecular bone of all cases, the IHC
reaction was strongly positive in correspondence of the
calcified bone matrix. In contrast, the osteoid seams were
not stained. Some positive osteocytes were found in all
cases within the calcified bone matrix. Sometimes, positive
osteocytes were also present in correspondence of the
osteoid seams, mainly next to plump osteoblasts (Fig. 4). In
agreement with these findings, ISH showed a positive
signal within some osteocytes localized in both the calcified
matrix and in the osteoid (Fig. 5).
Fig. 2 Total MGP: (a1, b1, and c1) negative (empty arrows) and/or
positive (arrows) osteoclasts to IHC are visible; (a2, b2, and c2)
sections adjacent to a1, b1, and c1, respectively: the same osteoclasts
positive to IHC in a1, b1, and c1 are also positive to ISH (arrow).
Trabecular bone, hyperparathyroidism. Bars=10 μm
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In all samples, with the only exception of the case with
adynamic osteodystrophy in which active osteoblasts were
not found, most of the plump osteoblasts were lightly or
intensely stained by the fetuin-A IHC reaction (Fig. 4). Such
IHC positivity was confirmed by ISH reactivity (Fig. 5). No
differences were found between trabecular and cortical bone.
In bone samples characterized by increased turnover, cells
of endosteal fibrosis were positive to both IHC and ISH
reactions. Osteoclasts, in all cases in which these cells were
found, were negative to both IHC and ISH (Figs. 4 and 5).
In a few cases, some endosteal lining cells appeared
immunohistochemically positive and showed a ISH signal.
However, as described for MGP, the reaction products of
both IHC and ISH in these cells were sometimes hard to be
detected due to their very thin cytoplasm.
Discussion
All patients but two were affected by the wide spectrum
of bone cells and matrix alterations, ranging from high
to low bone turnover diseases, which are proper of renal
osteodystrophy [18].
For MGP IHC, antibodies against total, fully carboxylated,
and non-carboxylated proteins were tested, to evaluate the
carboxylation status of MGP. For each of the three forms of
MGP, the amino acid sequences recognized by the respective
monoclonal antibodies corresponded exactly to those of a
recent study performed in human arteries [11]. In the vascular
wall, the inhibition of γ-carboxylation of Glu residues
yielded the undercarboxylation of MGP and the subsequent
calcification of the tunica media [10]. Moreover, it has been
shown in the bone tissue of transgenic mice, which produced
two distinct mutated forms of MGP in osteoblasts, that the
Gla residues are required for MGP antimineralization
function [21].
In all patients, the calcified bone matrix was almost
completely negative to the antibody directed against the total
MGP. This result is similar to that obtained by Spronk et al.
[22] in human fetal bone, by using two monoclonal
antibodies, against the N- and C-terminus of MGP. In
contrast, Carlson et al. [23] reported slight positive IHC
staining for total MGP in widely scattered areas of calcified
matrix in vertebrae of monkeys. Such variation in immuno-
Fig. 4 Fetuin-A, IHC: a osteoblasts with variable intensity of
positivity are present (arrows); b osteoblasts are highly positive
(arrows). In both a and b, endosteal fibrosis cells (asterisks) and some
osteocytes (arrowheads) are positive, while osteoclasts are negative
(empty arrows); a clear positivity of calcified bone matrix is visible,
while the osteoid seams are negative (white asterisks). Trabecular
bone, hyperparathyroidism. Bars=20 μm
Fig. 3 Carboxylated MGP, IHC: a osteoblasts (arrows) and some
osteocytes (arrowheads) are positive, the osteoid seam is barely
stained (white asterisk); b one almost negative (empty arrow) and
three positive (arrows) osteoclasts, together with positive endosteal
fibrosis cells (asterisk) within the Howship’s lacuna, are visible. In
both a and b, a diffuse positivity of calcified bone matrix is present.
Trabecular bone, hyperparathyroidism. Bars=10 μm
268 Virchows Arch (2009) 454:263–271
reactivity might be due to the different animal species or,
most probably, to differences in the sequences recognized by
the various monoclonal antibodies. In any case, the calcified
matrix in all bone biopsies of the present study was lightly
and diffusely immunostained for carboxylated MGP.
Among bioptical samples, only some occasional osteoid
seams were immunostained for total MGP in one case with
hyperparathyroidism and one with osteomalacia. In human
fetal bone, Spronk et al. [22] reported a weak total MGP
signal that was associated with the extracellular matrix at
sites of non-calcified bone. Moreover, Carlson et al. [23]
found some areas of osteoid seams positive to total MGP.
These authors suggested that the presence of MGP within
the osteoid tissue might have a role in preventing its
premature mineralization. In the present study, in contrast to
total MGP, a very faint positivity to carboxylated MGP was
found in most osteoid seams in all types of bone conditions.
In all bone biopsies, osteoblasts were invariably positive
to total MGP. Some IHC positive osteoblasts were also
found by Carlson et al. [23]. In our samples, these cells
were also positive to the carboxylated form of MGP.
Moreover, they expressed the MGP gene. This result
appears especially significant on the basis of the contradic-
tory reports available in the literature. Using ISH, Hirakawa
et al. [24] could not detect MGP mRNA in rat osteoblasts,
although the authors were aware that it had been detected in
osteoblastic cell culture. Luo et al. [25] also did not find
MGP mRNA by ISH in mouse osteoblasts; they hypothe-
sized, therefore, that, like fetuin-A, the protein could
accumulate in bone through blood circulation. In biopsies
of human fracture callus, the signal for MGP mRNA was
only found in osteoblasts of the woven bone in non-unions,
and not in osteoblasts of the old bone [26].
In our bioptical samples, not only osteoblasts, but also
some osteocytes, especially those that appeared to be the
youngest, were positive to total MGP IHC. This is in
contrast with the results of Carlson et al. [23] who found
negative osteocytes. However, in our experience, osteocytes
were also positive to the carboxylated form of MGP and
expressed MGP mRNA. These results are in line with the
osteoblastic origin of the osteocytes. Also the findings that
some endosteal lining cells are immunostained for the total
and carboxylatedMGP protein and express the corresponding
mRNA are in agreement with the origin of the lining cells
from the osteoblasts. Similarly, the observation that the cells
of endosteal fibrosis that accumulate in bone marrow in cases
of hyperparathyroidism are positive to both total and
carboxylated MGP and express the corresponding mRNA
might depend on the fact that these cells are probably
osteoblast precursors, secondary to parathormone-stimulated
proliferation of bone marrow stromal cells [27].
The present study has shown that most osteoclasts are
immunostained for total MGP in any type of bone
condition, a result in agreement with the findings of
Carlson et al. [23]. In our experience, the same cells are
immunostained for the carboxylated MGP, too, and ISH has
shown that they express the corresponding mRNA.
Undercarboxylated MGP immunostaining was almost
negative in all bioptical samples, although some very light
positivity was found in a minority of cases in calcified or
uncalcified bone matrix and in bone cells. This indicates
that the MGP protein present in bone, where calcification is
a physiological event, is predominantly in its active form,
and demonstrates that, at least locally, there is not a
significant vitamin K deficiency. Interestingly, in the intima
of atherosclerotic arteries and in Mönckeberg’s sclerosis of
the media, where pathological calcifications of different
etiologies occur, undercarboxylated MGP was almost
exclusively localized in sites of calcification, while total
and carboxylated MGP were mostly found in the non-
calcified areas of the tunica media [11].
The IHC localization of fetuin-A in the mineralized areas
of bone matrix has been already described in normal adult
humans [28] and other mammals [29, 30]. Our results show
that the protein is highly represented in mineralized matrix
of normal bone of uremic patients, as well as in any form of
renal osteodystrophy, independent of the rate of bone
Fig. 5 Fetuin-A, ISH: a, b Osteoblasts (arrows) and some osteocytes
(arrowheads) and endosteal fibrosis cells (asterisks) are positive. In b,
a negative osteoclast is present (empty arrow). Trabecular bone,
hyperparathyroidism. Bars=20 μm
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turnover and of the type (lamellar or woven) of bone
structure. Osteoid seams were invariably negative: in this
respect, no comparative data could be found in the
literature.
It is a general opinion, ensued from old findings [28, 31]
and confirmed by relatively recent studies [32, 33], that
fetuin-A is synthesized in the liver and is incorporated, via
the bloodstream, into the bone matrix during the mineral-
ization process, as a result of its high affinity for
hydroxyapatite [2, 12, 34, 35]. In the present study, most
osteoblasts were immunostained for fetuin-A in all types of
renal osteodystrophy, as well as in normal bone. Our IHC
and ISH findings demonstrate that human osteoblasts do
have fetuin-A in the cytoplasm and synthesize it. To our
knowledge, these results were not previously described in
humans, although some IHC positivity of the rat counter-
part of human fetuin-A had been found in osteoblasts of
adult rats [29]. Moreover, in a very recent paper, some
fetuin-A uptake by osteoblast-like cells was reported [36].
On the basis of our results, the localization of fetuin-A in
the mineralized bone matrix appears to be due to an active
osteoblast participation, rather than to a mere accumulation
of the protein from the blood. The previously reported
osteoblast negative results could be probably explained, at
least in part, by hypothesizing that the degree of synthesis
of fetuin-A in bone of adult humans could be much lower
than that in the liver, as it was found in mouse osteoblastic
cells [37] and for the rat counterpart of the protein [38].
With reference to fetuin-A, no previous papers dealing
with osteocytes in humans have been found. Our results
show that some osteocytes are both IHC and ISH positive.
Similarly, the IHC positivity of the rat counterpart of human
fetuin-A was described in osteocytes of adult rats [29]. As
commented above for MGP, these findings, as well as the
positivity to both reactions in some endosteal lining cells
and cells of endosteal fibrosis in hyperparathyroidism are in
agreement with the osteoblastic relationship of these cells.
In vitro experiments have suggested that fetuin-A, and
its rat counterpart, might stimulate bone resorption [39, 40].
Moreover, it has been hypothesized that osteoclasts may
clear the calciprotein particles by phagocytosis [14], thus
mediating the recycling of extracellular calcium and
phosphate from basic calcium phosphate. However, in our
study, osteoclasts were negative to both fetuin-A IHC and
ISH, so that no information could be drawn on fetuin-A
involvement in bone resorption.
In conclusion, we have examined, for the first time, the
localization and the synthesis of fetuin-A and MGP, directly
in the bone tissue of patients with chronic renal failure in
HD treatment. In contrast with the general opinion that, in
adult humans, the fetuin-A is synthesized in the liver,
transported via the bloodstream to bone, and incorporated
in the calcified matrix, we have shown that it is produced
by osteoblasts, too. It is possible that the bone synthesis of
the protein can contribute to the formation within the BRC
of the calcium–phosphate–fetuin–MGP complex described
in rats by Price et al. [13]. The MGP protein, synthesized
by osteoblasts and accumulated in bone, is essentially of
carboxylated type, thus in its active form. Also, osteoclasts
synthesize MGP, which is contained in these cells in the
carboxylated form. This new finding suggests that these
cells, other than osteoblasts, can be an important source of
the calcium–phosphate–fetuin–MGP complexes. In agree-
ment with the findings in rats [12], these results point to the
increased bone turnover and specifically to the osteoclastic
resorption as important factors which can promote extra-
skeletal and arterial calcifications in uremia. However,
further studies are necessary to confirm whether the
calcium–phosphate–fetuin–MGP complexes, detected un-
der some circumstances in rats, are also present in humans,
and particularly in uremic patients with artery and soft
tissue calcifications [12].
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